Agenix   
Agenix创建于1982年，该公司是基于昆士兰理工学院成立的一个生物制药和研究集团，该公司的主要业务是研发单克隆抗体诊断程序。该公司拥有两个全资子公司，其中一个为Agen Biomedical，另一个为Agenix Biopharmaceutical，后者位于中国上海。

Agenix listed on the Australian Securities Exchange in 1987. Today, Agenix’s lead product
candidate is ThromboView®, a novel radio-labelled monoclonal antibody imaging modality for
pulmonary embolism (PE) and deep vein thrombosis (DVT). ThromboView® has successfully
completed two U. S.  FDA Phase II clinical trials and is in partnering discussions for Phase III trials.

Agenix’s human health diagnostics platform, DiagnostIQ® is a patented disposable point-ofcare test device with reader. DiagnostIQ® utilises an antibody/antigen printed membrane, a unique pre-filter device and an incubation chamber in a flow-through format to create a
sensitive and quantitative, rapid, test. The patented technology provides the potential for point-of-need testing that is simple and quick to use, gives rapid and accurate results. Agricultural rights for the platform are licensed to Bayer CropSciences AG.

Agenix has completed pre-clinical studies on AGX 1009, a next-generation reverse
transcriptase inhibitor (NtRTI) prodrug of tenofovir. Agenix plans to divest this project and exit
China operations following filing of the CFDA clinical trial application in 3Q 2013 to focus on its
diagnostics business. Agenix owns all the patent rights to both ThromboView® and AGX 1009.